Literature DB >> 28877346

Comparable Outcome of Out-of-Hospital Cardiac Arrest and In-Hospital Cardiac Arrest Treated With Extracorporeal Life Support.

Omar Ellouze1, Melitine Vuillet1, Justine Perrot1, Sandrine Grosjean1, Anis Missaoui1, Serge Aho2, Ghislain Malapert3, Belaid Bouhemad1, Oliver Bouchot3, Claude Girard1.   

Abstract

Extracorporeal life support (ECLS) has shown benefits in the management of refractory in-hospital cardiac arrest (IHCA) by improving survival. Nonetheless, the results concerning out-of-hospital refractory cardiac arrests (OHCA) remain uncertain. The aim of our investigation was to compare survival between the two groups. We realized a single-center retrospective, observational study of all patients who presented IHCA or OHCA treated with ECLS between 2011 and 2015. Multivariate analysis was realized to determine independent factors associated with mortality. Over the 4-year period, 65 patients were included, 43 in the IHCA group (66.2%), and 22 (33.8%) in the OHCA group. The duration of low flow was significantly longer in the OHCA group (60 vs. 90 min, P = 0.004). Survival to discharge from the hospital was identical in the two groups (27% in the OHCA group vs. 23% in the IHCA group, P = 0.77). All surviving patients in the OHCA group had a cerebral performance categories score of 1-2. In multivariate analysis, we found that the initial lactate level and baseline blood creatinine were independently associated with mortality. We found comparable survival and neurological score in patients who presented IHCA and OHCA treated with ECLS. We believe that appropriate selection of patients and optimization of organ perfusion during resuscitation can lead to good results in patients with OHCA treated with ECLS.
© 2017 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Keywords:  -Cardiac arrest; -Cardiopulmonary resuscitation; Extracorporeal life support

Mesh:

Year:  2017        PMID: 28877346     DOI: 10.1111/aor.12992

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  6 in total

1.  Automated infrared pupillometry for neurological prognostication after extracorporeal cardiopulmonary resuscitation.

Authors:  Omar Ellouze; Tiberiu Constandache; Vivien Berthoud; Pierre Voizeux; Belaid Bouhemad; Pierre-Grégoire Guinot
Journal:  Intensive Care Med       Date:  2020-01-16       Impact factor: 17.440

2.  Predictors of survival and neurologic outcome for adults with extracorporeal cardiopulmonary resuscitation: A systemic review and meta-analysis.

Authors:  Junhong Wang; Qingbian Ma; Hua Zhang; Shaoyu Liu; Yaan Zheng
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

3.  Perfusion parameters and target values during extracorporeal cardiopulmonary resuscitation: a scoping review protocol.

Authors:  Lars Saemann; Christine Schmucker; Lisa Rösner; Friedhelm Beyersdorf; Christoph Benk
Journal:  BMJ Open       Date:  2019-08-30       Impact factor: 2.692

Review 4.  Extracorporeal cardiopulmonary resuscitation for adults with shock-refractory cardiac arrest.

Authors:  Dennis Miraglia; Jonathan E Ayala
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-01-18

5.  Neurological outcome after extracorporeal cardiopulmonary resuscitation for in-hospital cardiac arrest: a systematic review and meta-analysis.

Authors:  Benjamin Yaël Gravesteijn; Marc Schluep; Maksud Disli; Prakriti Garkhail; Dinis Dos Reis Miranda; Robert-Jan Stolker; Henrik Endeman; Sanne Elisabeth Hoeks
Journal:  Crit Care       Date:  2020-08-17       Impact factor: 9.097

6.  Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial.

Authors:  Omar Ellouze; Agnès Soudry Faure; Mohamed Radhouani; Osama Abou-Arab; Emmanuel Besnier; Mouhamed Moussa; Amélie Cransac; Elea Ksiazek; Marc-Olivier Fischer; Paul Michel Mertes; Belaid Bouhemad; Pierre Grégoire Guinot
Journal:  ESC Heart Fail       Date:  2021-06-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.